DERMATOLOGISTS1
STAY AHEAD OF ECZEMA
WITH DUPIXENT
DUPIXENT is a breakthrough treatment for uncontrolled moderate-to-severe eczema. When topical prescriptions aren’t enough, and your symptoms and flare-ups keep coming back, it may be time for a different kind of treatment.
DUPIXENT helps you stay ahead of symptoms—continuously treating eczema between flare-ups.
DUPIXENT is a biologic that helps block a key source of inflammation inside the body that can cause eczema.
DUPIXENT is not a steroid or immunosuppressant; it is a prescription biologic medicine given under the skin (subcutaneous injection).
A BREAKTHROUGH ECZEMA TREATMENT
DUPIXENT was studied in adults and children 6 months of age and older.
See the clinical results by choosing adults (18+ years), teens (12-17 years), children (6-11 years), or young children (6 months-5 years).
FOR ADULTS
(18+ YEARS)
DUPIXENT was studied in 3 clinical trials with more than 2,100 adults with moderate-to-severe eczema not well controlled with topical prescription treatments. It was first approved by the FDA for this patient population on March 28, 2017.
View Results inAdults
See before and after pictures
Cristal,
Real patient. Individual results may vary.
FOR TEENS
(12-17 YEARS)
DUPIXENT was studied in a 16-week clinical trial with 251 patients ages 12-17 years with moderate-to-severe eczema not well controlled with topical prescription treatments. It was approved by the FDA for this patient population on March 11, 2019.
View Results inTeens
See before and after pictures
Tyler,
Real patient. Individual results may vary.
FOR CHILDREN
(6-11 YEARS)
DUPIXENT was studied in a 16-week clinical trial with 367 patients ages 6-11 years with severe eczema not well controlled with topical prescription treatments. It was approved by the FDA for the moderate-to-severe patient population on May 26, 2020.
View Results inChildren
See before and after pictures
Harper,
Real patient. Individual results may vary.
FOR YOUNG CHILDREN
(6 MONTHS-5 YEARS)
DUPIXENT was studied in a 16-week clinical trial with 162 patients ages 6 months to 5 years with moderate-to-severe eczema not well controlled with topical prescription treatments. It was approved by the FDA for the moderate-to-severe patient population on June 7, 2022.
View Results inyoung children
See before and after pictures
Not an actual patient.
Individual results may vary.
Sean, real patient.
Individual results may vary.
TAKE YOUR SHOT AGAINST ECZEMA
It’s time to get ahead of your symptoms, so help put uncontrolled moderate-to-severe eczema in its place with DUPIXENT. Be proactive and take control with one dose every 2 or 4 weeks based on age and weight (after initial loading dose of 2 injections) for adults and children 6 years and older. For children aged 6 months to 5 years, one dose every 4 weeks based on weight, with no initial loading dose recommended.
Your doctor will tell you how much DUPIXENT to inject and how often to inject it, following proper training. DUPIXENT is an injection given under the skin (subcutaneous injection). It can be given by a doctor in the office or a caregiver at home:
- in children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.
- in children 12 years of age and older, DUPIXENT should be given by or under the supervision of an adult
DUPIXENT MyWay® COPAY CARD
The DUPIXENT MyWay Copay Card may help eligible patients reduce the out-of-pocket cost of DUPIXENT. If you’re eligible, you can sign up and your card will be sent via email. Terms & Restrictions Apply.
See Copay DetailsDUPIXENT MyWay also offers Nurse Educator support, supplemental
injection training online or in person, and more.
GET MORE SUPPORT
Get exclusive emails, resources, and more
support from DUPIXENT MyWay®.
REAL PATIENT EXPERIENCES
Everyone has a story to tell. Hear from DUPIXENT
ambassadors as they share their messages and
lessons they’ve learned.
Kiara,
Real patient. Individual results may vary.
Find a Specialist Who
Treats Eczema
Use this Healthgrades™ tool to easily find nearby
specialists with experience in treating children , teens,
and adults with uncontrolled moderate-to-severe
eczema (atopic dermatitis).